3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer -

Cervical cancer vaccine wins some conservative favor

CancerNov 22, 05

Conservatives who fought against wider access to a “morning-after” pill are speaking favorably about vaccines against a sexually transmitted cause of cervical cancer, but some groups may still call for limited use.

The makers of the still-experimental vaccines, Merck & Co. Inc. and GlaxoSmithKline Plc, have been meeting with advocacy groups to dispel any concerns that giving the shots might promote sexual activity by young girls.

The efforts are paying off, as some religious organizations are welcoming the vaccines as a new weapon against the sexually transmitted human papillomavirus (HPV), the most common cause of cervical cancer.

“We think it’s a great idea to have this vaccine,” said Dr. Gene Rudd, associate executive director of the Christian Medical and Dental Association. Should studies continue to show solid results, “we think it ought to be a recommended vaccine,” he said.

Rudd’s organization was among the opponents of Barr Pharmaceuticals Inc.‘s bid for over-the-counter sales of the Plan B “morning-after” contraceptive. Some Plan B backers worry the same forces will stymie the HPV vaccines by arguing their availability could clash with a message promoting abstinence.

“We do not want to see another instance of ideology trumping the health and well-being of the American people,” Sen. Hillary Rodham Clinton, a New York Democrat, wrote in a letter to Health and Human Services Secretary Mike Leavitt.

Cervical cancer strikes about 10,000 U.S. women a year and kills about 3,900, according to the American Cancer Society.

Merck’s vaccine has shown 100 percent protection from the two most common HPV strains and could win approval next year.

For maximum acceptance, the makers need a strong endorsement from the Advisory Committee for Immunization Practices, a panel convened by the Centers for Disease Control and Prevention. Schools often follow the panel’s recommendations when deciding which vaccines to require for students.

While some physicians suggest mandatory vaccination for girls—possibly at age 11 or 12—others want the shots limited to those at high risk of HPV infection because they have multiple sexual partners.

“You can’t get HPV through casual contact, and if you limit your sexual behavior…you’re not going to have to worry about HPV,” said Dr. Hal Wallis of the Physicians Consortium, which advocates abstinence until marriage.

By requiring universal vaccination, “we would be literally vaccinating millions of women who really are at no risk at all,” he said.

Urging limits could be a “back-door way” for opponents to defeat the vaccines, said Dr. Susan Wood, a women’s health expert who left the Food and Drug Administration because of its refusal to clear over-the-counter Plan B. Just as with Plan B, opponents “don’t want widespread availability,” she said.

Concerned Women for America, a conservative group that lobbied against Plan B, has no position on the vaccines yet.

“People do seem more willing to take risks if they think they are not going to suffer consequences,” said Wendy Wright, CWA’s executive vice president. She said she was “encouraged” Merck was pitching the vaccine as preventing cancer, rather than a sexually transmitted infection. That could avoid “the very touchy issue of how this virus is transmitted,” she said.

Executives from Merck and Glaxo said they are sensitive to concerns from groups that teach abstinence.

“Abstinence obviously is the most effective approach to preventing cervical cancer, but there are many other potential outcomes,” Margaret McGlynn, president of Merck Vaccines, said at the Reuters Health Summit this month.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site